Mini Review Open Access
Neurological biomarkers in adolescent and young adult populations with hyperuricemia and gout: diagnostic potential and clinical implications
Yue Zhang1,2,3,*,#, Xiaoying Zhu4,#, Bohong Gao1,#, Kamel Meguellati5,*, Cibo Huang6,7,8,*, Guisong Wang9
- #Contributed equally
- 1Weilan Translational Institute of Biomicromolecules Research, Shenzhen, Guangdong, China
- 2Hezhou (the City of Longevity) Dongrong Yao Medicine Research Institute, Joint Institute of Shenzhen University and Hezhou Hospital for Traditional Chinese Medicine, Hezhou, Guangxi, China
- 3Integrated Chinese and Western Medicine Research Institute, TORAMI Avatar Longevity and Healthcare Hub, Zheng He Hospital, Changsha, Hunan, China
- 4Department of Rheumatology and Immunology, The First Clinical College of Harbin Medical University, Harbin, China
- 5College of Pharmacy, Jinan University, 855 Xingyu Avenue East, Guangzhou, 511436, China
- 6Shenzhen Hospital for Integrated Chinese and Western Medicine, Shenzhen, Guangdong, China
- 7Department of Rheumatology, Immunology and Gerontology, South-China Hospital of Shenzhen University, Shenzhen, Guangdong, China
- 8Department of Rheumatology and Immunology, National Center of Gerontology, Beijing Hospital, Beijing, China
- 9Shanghai East Brain Research Institute, and Department of Neurosurgery, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China
Corresponding Author
Yue Zhang, humanoids101@163.com; Kamel Meguellati, kameljilin@yahoo.fr; Cibo Huang, huangcibo1208@139.com
Received Date: February 05, 2026
Accepted Date: March 09, 2026
Zhang Y, Zhu X, Gao B, Meguellati K, Huang C, Wang G. Neurological biomarkers in adolescent and young adult populations with hyperuricemia and gout: diagnostic potential and clinical implications. Curr Res Orthop. 2026;1(1):1-6.
Copyright: © 2026 Zhang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Effect of educational level on Alzheimer's disease-related biomarkers: Commentary
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairments that might be accompanied by declines in activities of daily living, neuropsychiatric disorders and a loss of motor function [1,2]. At present, the prevalence of dementia of Alzheimer’s type (DAT) is approximately 4% among elderly people [3]. With the increase in the aging the population, the number of individuals with DAT is still increasing.
Identification and validation of N7-methylguanosine-associated gene NCBP1 as prognostic and Prognostic immune-associated biomarkers in breast cancer patients
Epigenetics is the study of heritable modifications to gene expression, such as DNA methylation, histone modifications, and RNA modifications, that do not alter the nucleotide sequence of the corresponding gene. Recently, RNA modification has emerged as a novel research focus.
Perspective study of UPR signaling molecules as potential biomarkers in bone metabolism
The skeletal system consists mostly of extracellular matrix and mineral salts. Osteoblasts and chondrocytes create enormous amounts of extracellular matrix proteins for skeletal systems to grow and sustain. Many skeletal metabolism related proteins are produced by endoplasmic reticulum (ER) and secrete outside cell membrane then form to extracellular oligometric matrix proteins and collagens.
Biomarkers for monoclonal antibody targeting EGFR in NSCLC: Challenges, current status, and future perspectives
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths [1]. However, significant improvements in the past decades have been achieved with improved outcomes [2-4]. Several mutations have been described as promoters of oncogenesis, and specific treatments are available, including those for Epidermal Growth Factor (EGFR) mutations [4].
Reflex ordered testing for molecular biomarkers in lung adenocarcinoma: An update
Molecular biomarker testing is essential to the work up of metastatic and advanced non-small cell lung carcinoma. Despite molecular testing guidelines proposed by the National Comprehensive Cancer Network, Association for Molecular Pathology, and many others, multiple reports continue to indicate that lung cancer patients are inadequately tested for key molecular biomarkers. Within our hospital system, reflex ordered testing of a panel of molecular biomarkers in all newly diagnosed lung adenocarcinomas was approved and implemented in 2017.